Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Immunotherapy for arterial ischaemic stroke in childhood: a systematic review
Conclusions Immunotherapies are used in children with AIS, mainly as steroids for children with arteriopathy. However, there is currently little robust evidence to either encourage or discourage this practice. There is weak evidence consistent with the hypothesis that in certain children at risk, steroids may both reduce the risk of occurrent/recurrent stroke and enhance neurological outcomes. As the potential benefit is still uncertain, this indicates that a trial of steroids in childhood AIS may be justified.
Source: Archives of Disease in Childhood - April 19, 2017 Category: Pediatrics Authors: Edwards, H. B., Mallick, A. A., O'Callaghan, F. J. K. Tags: Clinical trials (epidemiology), Epidemiologic studies, Immunology (including allergy), Stroke, Child health Original article Source Type: research

Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research

Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature.
We report herein incidence and clinical features of hyperacute onset PCD, a vertebrobasilar stroke mimic. We performed a retrospective analysis of all suspected PCD cases referred to the Udine University Hospital between 2009 and 2017. Our center provides the only neuroimmunology laboratory for three provinces of the Friuli-Venezia Giulia region, Italy (983,190 people as of January 1, 2017). Inclusion criteria were (1) abrupt onset of neurological symptoms; (2) initial consideration of a vascular etiology; (3) final diagnosis of "definite PCD." We also carried out a systematic review of the literature in order to identify ...
Source: Cerebellum - August 28, 2019 Category: Neuroscience Authors: Vogrig A, Bernardini A, Gigli GL, Corazza E, Marini A, Segatti S, Fabris M, Honnorat J, Valente M Tags: Cerebellum Source Type: research

Vasculitic neuropathy following exposure to minocycline
Conclusions: Our findings suggest that the typical neuropathy associated with minocycline use is painful single or multiple mononeuropathy due to peripheral nerve vasculitis, which may also be accompanied by presumed CNS vasculitis (presenting as stroke).
Source: Neurology Neuroimmunology and Neuroinflammation - November 12, 2015 Category: Neurology Authors: Baratta, J. M., Dyck, P. J. B., Brand, P., Thaisetthawatkul, P., Dyck, P. J., Engelstad, J. K., Goodman, B., Karam, C. Tags: All Cerebrovascular disease/Stroke, Other cerebrovascular disease/ Stroke, All Immunology, Autoimmune diseases, Vasculitis Article Source Type: research

Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature
We report herein incidence and clinical features of hyperacute onset PCD, a vertebrobasilar stroke mimic. We performed a retrospective analysis of all suspected PCD cases referred to the Udine University Hospital between 2009 and 2017. Our center provides the only neuroimmunology laboratory for three provinces of the Friuli-Venezia Giulia region, Italy (983,190 people as of January 1, 2017). Inclusion criteria were (1) abrupt onset of neurological symptoms; (2) initial consideration of a vascular etiology; (3) final diagnosis of “definite PCD.” We also carried out a systematic review of the literature in order to ident...
Source: The Cerebellum - August 28, 2019 Category: Neurology Source Type: research

Meningioma preceding CASPR2 antibody limbic encephalitis with a stroke mimic: A case report
We report a contactin-associated protein-like 2-antibody (CASPR2-Ab)-positive patient who presented with atypical LE. Diagnoses: CASPR2-Ab-positive LE was the presumed diagnosis. Re-evaluation of cerebrospinal fluid (CSF) samples revealed autoantibodies targeting CASPR2 at an immunoglobulin G titer of 1:1. The clinical presentation of subacute onset seizures, abnormal electroencephalography, hypermetabolism on positron emission tomography, good immunotherapy response, and the presence of specific antibodies in serum supports a diagnosis of autoimmune LE. Intervention: The patient received glucocorticoids (1...
Source: Medicine - June 11, 2021 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Sphingosine ‐1‐phosphate receptor modulators in stroke treatment
AbstractSphingosine-1-phosphate (S1P) is a bioactive lysophospholipid that can influence a broad range of biological processes through its binding to five distinct G protein-coupled receptors. S1P receptor modulators are a new group of immunosuppressive agents currently used in the immunotherapy of multiple sclerosis. Inflammation following stroke may exacerbate injury. Given that S1P signaling is linked to multiple immune processes, therapies targeting the S1P axis may be suitable for treating stroke. In this review, we outline S1P metabolism and S1P receptors, discuss the mechanisms of action of S1P receptor modulators i...
Source: Journal of Neurochemistry - August 9, 2022 Category: Neuroscience Authors: Wanzhou Zhang, Yudi Li, Fangming Li, Li Ling Tags: REVIEW Source Type: research

GLUTAMATE RECEPTOR ANTIBODIES IN NEUROLOGICAL DISEASES: Anti-AMPA-GluR3 antibodies, Anti-NMDA-NR1 antibodies, Anti-NMDA-NR2A/B antibodies, Anti-mGluR1 antibodies or Anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjogren's syndrome, Schizophrenia, Mania or Stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate Blood Brain Barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and Ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Abstract Glutamate is the major excitatory neurotransmitter of the Central Nervous System (CNS), and it is crucially needed for numerous key neuronal functions. Yet, excess glutamate causes massive neuronal death and brain damage by excitotoxicity-detrimental over activation of glutamate receptors. Glutamate-mediated excitotoxicity is the main pathological process taking place in many types of acute and chronic CNS diseases and injuries. In recent years, it became clear that not only excess glutamate can cause massive brain damage, but that several types of anti-glutamate receptor antibodies, that are present in ...
Source: Herpes - August 1, 2014 Category: Infectious Diseases Authors: Levite M Tags: J Neural Transm Source Type: research

Suppressing NK Cells by Astragaloside IV Protects Against Acute Ischemic Stroke in Mice Via Inhibiting STAT3
In conclusion, ASIV inhibits post-ischemic brain infiltration and activation of NK cells through STAT3 suppression, and this inhibitory effect of ASIV on NK cells plays a key role in its protection against acute ischemic brain injury. Our findings suggest that ASIV is a promising therapeutic candidate in NK cell-based immunotherapy for the treatment of acute ischemic stroke and pave the way for potential clinical trials.
Source: Frontiers in Pharmacology - February 3, 2022 Category: Drugs & Pharmacology Source Type: research

SNMMI 2020: PET radiotracer measures stroke recovery
A new PET radiotracer may one day help clinicians evaluate stroke recovery,...Read more on AuntMinnie.comRelated Reading: SNMMI 2020: PET/MRI finds location of chronic pain in patients SNMMI 2020: How nuclear medicine handled COVID-19 SNMMI 2020: Radionuclide treatment paves way for immunotherapy SNMMI 2020: Medical students key to the specialty's future Digital FDG-PET offers insights into hearing loss
Source: AuntMinnie.com Headlines - July 15, 2020 Category: Radiology Source Type: news

Novel immunotherapy boosts long-term stroke recovery in mice
(University of Pittsburgh) Specialized immune cells that accumulate in the brain in the days and weeks after a stroke promote neural functions in mice, pointing to a potential immunotherapy that may boost recovery after the acute injury is over, University of Pittsburgh School of Medicine neurologists found.
Source: EurekAlert! - Medicine and Health - May 19, 2021 Category: International Medicine & Public Health Source Type: news

Antiphospholipid Syndrome-induced Ischemic Stroke Following Pembrolizumab: case report and systematic review
We report a case of a patient treated with pembrolizumab who developed an acute ischemic stroke (AIS) as manifestation of immunotherapy-induced antiphospholipid syndrome (APS) and provide a systematic review of the literature.
Source: Lung Cancer - August 3, 2021 Category: Cancer & Oncology Authors: Vito Tota, Marie Dagonnier, Didier Wery, Laure Binet, Nathalie Nagy, Val érie Durieux, Marie Diaz, Jose-Antonio Elosegi, Stéphane Holbrechts Tags: Review Source Type: research

Identification of pyroptosis-related immune signature and drugs for ischemic stroke
Conclusion: Our findings lay a foundation for further research on pyroptosis and IS systemic inflammation, to improve IS prognosis and its responses to immunotherapy.
Source: Frontiers in Genetics - September 27, 2022 Category: Genetics & Stem Cells Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Arterial Spin Labeling Imaging Characteristics of Anti-leucine-rich Glioma-Inactivated 1 Encephalitis: A Qualitative and Quantitative Analysis
DiscussionIn this preliminary study of six patients, we demonstrate an ASL hyperperfusion pattern, with a possible predilection for the right mesial temporal lobe on both qualitative and quantitative assessments in patients with seropositive LGI1. Larger scale studies are necessary to further characterize the strength of these associations.
Source: Frontiers in Neurology - July 28, 2022 Category: Neurology Source Type: research